U.S. News & World Report ranked our pediatric orthopaedic program 19th nationally in 2022–2023, in collaboration with Shriners Children’s Northern California, our longstanding partner on orthopedic disorders and spinal injuries.
Cellular therapy improves signs, symptoms of Duchenne muscular dystrophy
A clinical trial at UC Davis Health and six other sites showed that cellular therapy offers promise for patients with late-stage Duchenne muscular dystrophy (DMD), a rare progressive genetic disorder that mostly affects boys. The therapy has shown to be safe and effective in stopping the deterioration of upper limb and heart functions. It is the first treatment to lead to meaningful functional improvements in the most severe cases of DMD patients.
Training the next generation of scientists in musculoskeletal research
The Departments of Orthopaedic Surgery and Biomedical Engineering received the prestigious National Institutes of Health T32 training program grant. The award boosts the departments’ capacity to train and educate the next generation of scientists in musculoskeletal research. The UC Davis joint project is called MUsculoSkeletal Clinical Learning Experience (MUSCLE) and will provide students with broad investigational experience in biomechanics, tissue engineering and regeneration of connective tissues, and translational/ applied research.